Status:
UNKNOWN
Evaluation of Long-term Health Status and Quality of Life in Adult Survivors With Philadelphia-negative Acute Lymphoblastic Leukemia/Lymphoma Treated With an Intensive Pediatric or Pediatric-inspired Protocol
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Lymphoma
Eligibility:
All Genders
25-70 years
Brief Summary
The overall survival of adult patients (15-59y) with Philadelphia-negative acute lymphoblastic leukemia/lymphoma (ALL/LL) was dramatically improved by the use of full pediatric or pediatric-inspired p...
Eligibility Criteria
Inclusion
- Patient with Philadelphia-negative ALL or LL treated in or according to a pediatric-like or pediatric-inspired protocol (GRAALL03/05-LL03-FRALLE2000) with or without allogeneic transplant.
- Patients older than 15 years old and less than 60 years old at diagnosis
- Patient with a follow-up from first complete remission of more than 10 years,
- Patient who gave informed signed consent for baseline examination
Exclusion
- Patient who experienced ALL/LL relapse within the 5 past years.
- Philadelphia positive ALL patients
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04677231
Start Date
January 1 2021
End Date
March 1 2024
Last Update
December 21 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.